Merck Cozaar Receptor Affinity Difference Not Clinically Relevant - FDA
Executive Summary
Merck Cozaar (losartan) claims regarding uniqueness in angiotensin II receptor binding have not been shown to be clinically relevant, FDA said in a Dec. 22 letter to Merck.